ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term

Pharmaceutical Technology

At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented.

pharminent May 15, 2026 (Last updated: May 21, 2026)

Pharmaceutical Technology

At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly’s Zepbound (tirzepatide) in sustaining weight loss was presented.

Related Stories